(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up - 2NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
- 3Russia earning billions from Hormuz blockade, German trade body says
- 4Comet MAPS faces a make-or-break moment as it dives toward the sun on April 4 — could it shine in the daytime sky?
- 5Orbán orders stop to gas deliveries to Ukraine via Hungary from July
- Inside the cockpit of RAF tanker during defensive mission against Iranian drones
- Opening Your True capacity: 12 Techniques for Personal growth
- True serenity: Investigating Emotional well-being and the Advantages of Contemplation
- Volkswagen in talks with defence firms on use of Germany plant: CEO
- EU Commission prepares €90bn Ukraine loan despite Hungary's veto
- The 10 Most Noteworthy Games in History
- ‘Dying of thirst’: Inside Gaza’s al-Mawasi water crisis
- Limited Rain Chances in Brazil Boost Coffee Prices
- Toddler given just 3 years to live after strange symptoms makes full recovery
